Search Results - solomon+snyder

5 Results

Sort By:

Novel Therapeutic Drug for Multiple Sclerosis

INVENTION NOVELTY This molecule, through its action on a unique target that is different from current therapeutic treatments for MS, has both immunosuppressive and neuromodulatory properties that will better prevent the progression of MS and repair the neuronal damage caused by the immune cells in MS. Currently, there are no MS drugs in the market...

Published: 5/9/2024 | Inventor(s): Paul Kim, Michael Kornberg, Peter Calabresi, Solomon Snyder

Keywords(s): Chronic Inflammatory Diseases, CNS and Neurological Disorders, Disease Indication, Multiple Sclerosis, Multiple Sclerosis (MS), Neurodegeneration, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Modulation of Oxidative Stress as a Therapeutic Pathway in Trigeminal Neuralgia

Unmet NeedTrigeminal neuralgia is a condition that affects the fifth cranial nerve, caused either via trigeminal nerve compression or secondary to another medical condition (i.e., multiple sclerosis, facial injury, tumors, etc.). Trigeminal neuralgia results in severe orofacial pain that is exceptionally debilitating, with a profound effect on one’s...

Published: 5/10/2024 | Inventor(s): Michael Lim, Solomon Snyder, Risheng Xu, Chirag Vasavda, Ryan Dhindsa

Keywords(s):

Category(s): Clinical and Disease Specializations, Technology Classifications, Technology Classifications > Therapeutic Modalities > Small Molecules

Treatment of Drug Abuse by Preventing GAPDH Nitrosylation

C12097: Novel Treatment for Cocaine Drug AbuseNovelty: A novel therapeutic strategy for cocaine abuse using known compounds.Value Proposition: Cocaine is a powerful addictive stimulant that causes psychological dependence and brain damage. Currently there are no FDA-approved drug for cocaine addiction and overdose, even though it is one of the most...

Published: 5/9/2024 | Inventor(s): Solomon Snyder, Risheng Xu, Nilkantha Sen

Keywords(s): Addiction, Biomarker, CNS and Neurological Disorders, Disease Indication, Mechanism of Action Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Psychiatry > Addiction, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Psychiatry, Technology Classifications > Therapeutic Modalities

Method for Identifying Weight Gain Inducing Effects of Antipsychotic Drugs

Novelty: This invention is a method for screening for orexigenic (weight inducing) antipsychotic drugs.Value Proposition: Atypical antipsychotic drugs (AAPDs) have revolutionized the treatment of schizophrenia and other psychoses, however, certain AAPDs cause weight gain. Weight gain is a side effect that can make the drug less successful in the market....

Published: 5/9/2024 | Inventor(s): Cory Teuscher, Alex Huang, Sangwon Kim, Solomon Snyder

Keywords(s): Biomarker, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, In Vitro Diagnostics, Mechanism-of-action Biomarker, Metabolic Disorders, Psychiatric Diseases, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Metabolic Diseases, Clinical and Disease Specializations > Psychiatry, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities

Developing Anti-cancer Drugs by Blockade of IP6-HSP90 Binding

C05044: Developing Anti-cancer Drugs by Blockade of IP6-HSP90 BindingValue Proposition: A cellular enzyme known as inositol pyrophosphate 6 kinase 2 (IP6K2) has an important role in programmed cell death (apoptosis). JHU scientists discovered an interaction between IP6K2 and a protein known as Heat Shock Protein-90 (HSP90). Binding of IP6K2 with HSP90...

Published: 5/9/2024 | Inventor(s): Randen Patterson, Krishna Juluri, Katherine Sixt, Asif Mustafa, Damian Van Rossum, Anutosh Chakraborty, Michael Koldobskiy, Solomon Snyder

Keywords(s): Biomarker, Cancers, Cell Lines, Discovery/Research Tools, Disease Indication, Human Cell Lines, In Vitro Research Tool, Mechanism of Action Biomarker, Non-novel, Predicted Novelty, Repurposed, Target-based Screening Tool, Therapeutic Matter, Therapeutics, Translational Research Biomarker

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Technology Classifications > Research Tools > Human Cell Lines, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Research Tools > Assays